$ABBV - Today’s Research Reports on Stocks to Watch:

New Post Public Reply Private Reply Replies (0) Message Board
jonny_red32
491
$ABBV - Today’s Research Reports on Stocks to Watch: AbbVie and Progenics Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / September 14, 2018 / Both AbbVie and Progenics had data results this week for Wall Street to absorb. While shares of AbbVie saw gains on its data for Upadacitinib, an investigational oral agent engineered by the company to selectively inhibit JAK1 and is being studied as a once-daily therapy in atopic dermatitis, shares of Progenics were in the red on missing one endpoint in its phase 3 clinical trial testing of its prostate cancer imaging agent, 1404.

RDI Initiates Coverage on:

AbbVie Inc.
https://www.rdinvesting.com/report/?ticker=ABBV

Progenics Pharmaceuticals, Inc.
https://www.rdinvesting.com/report/?ticker=PGNX

AbbVie Inc. shares closed up 3.31% on about 4.8 million shares traded on Thursday. The company presented Upadacitinib longer-term (32-weeks) and patient reported outcomes data from its Phase 2b Atopic Dermatitis Study at 27th European Academy of Dermatology and Venereology Congress. Upadacitinib is an investigational oral agent engineered by the company to selectively inhibit JAK1. It is being studied as a once-daily therapy in atopic dermatitis and the Phase 3 clinical program was initiated last month. According to the results, across all doses, a significantly greater proportion of patients who remained on upadacitinib showed continuous improvements in skin lesions and pruritus (itch) at week 32 compared to patients re-randomized to placebo. Results also showed that at week 32, patients who switched from placebo to upadacitinib 30 mg at week 16 showed greater improvements in skin lesions and itch compared to those remaining on placebo.

Access RDI’s AbbVie Inc. Research Report at:
https://www.rdinvesting.com/report/?ticker=ABBV

Progenics Pharmaceuticals, Inc. shares closed down nearly 18% yesterday on about 6 million shares traded. The company saw its shares tank after reporting concerning top-line data for the phase 3 clinical trial testing of its prostate cancer imaging agent, 1404, on Wednesday. The study did not meet the other endpoint of sensitivity but did prove specific enough. Specificity was defined as the ability of 1404 to identify patients without clinically meaningful prostate cancer. According to the results, three independent readers of the scans put the specificity in the range of 71% to 75% with a 95% confidence interval of 64% to 80%- that is, 95% of the time, if the trial was repeated, the result would fall in that range. As for 1404 to identify patients with clinically significant disease, this number only came in at 47% to 51% among the three readers with a 95% confidence interval of 41% to 56%. The results indicated too many false-negative calls of patients who had prostate cancer but were deemed to not have clinically meaningful disease. "These top line Phase 3 results of 1404 are inconsistent with the prior Phase 2 data, which showed significantly higher sensitivity rates,” stated CEO Mark Baker. He added, "We are currently conducting a thorough analysis of the full data set to understand the factors that may have contributed to this outcome and determine the appropriate development path for this novel agent in patients with low-grade prostate cancer. We plan to complete this review in the next quarter."

Access RDI’s Progenics Pharmaceuticals, Inc. Research Report at:
https://www.rdinvesting.com/report/?ticker=PGNX

Our Actionable Research on AbbVie Inc. (NYSE: ABBV) and Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
Engineer by trade & Swing Trader at Heart!

Join Webull today and get up to 75 #FREE stocks!
Get started >> Register with my referral link now>> JOIN HERE NOW


CLICK TO SEE --> Engineer, Design,& Build Packaging Equipment






Scroll down for more posts ▼

Top 10 Most Recent News Articles

Holiday Grease Advice Shows Utility Work Up Close Today

Updated Category News Views 117

Butter and pan drippings are mundane right until they become a backed-up kitchen line on a crowded holiday afternoon. New Jersey American Water's Nov. 17, 2026 reminder is not glamorous utility news, and frankly it is not trying to be. It is a practical warning: fats, oils and grease can cool, harden and accumulate in household pipes and farther along the wastewater...

Continue Reading
BNY's December Conference Slot Merits a Careful Listen

Updated Category News Views 101

A 10:40 a.m. conference appearance can look like wallpaper on a market calendar, but BNY's scheduled December 9 discussion deserves more attention than that. Robin Vince, the chief executive, is set to speak at the Goldman Sachs Financial Services Conference in New York, and the company has plainly warned that the conversation may include forward-looking statements and...

Continue Reading
Xailient Tops NIST for Real-World AI Face Recognition

Updated Category News Views 58

In a world where bigger ain't always better, Xailient's latest triumph at NIST's face recognition test has set them apart. On November 17, 2026, the U.S. National Institute of Standards and Technology (NIST) crowned Xailient as the leader in face recognition accuracy for on-device AI, leaving 105 others in the dust. This ain't your run-of-the-mill achievement—it shows...

Continue Reading
SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 113

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading
ELEGOO's Formnext Push Tests a Broader 3D Ambition

Updated Category News Views 75

Frankfurt’s show floor is where product promises meet some very unforgiving eyeballs. ELEGOO arrived at Formnext 2026 with more than a refreshed machine or two: it is laying out a wider bet across resin printing, FDM printing, and 3D scanning. That matters because the company is no longer presenting itself as merely a supplier of affordable creator hardware. It wants to...

Continue Reading
Yeahka Bids to Lead AI Shopping Evolution

Updated Category News Views 43

AI Shopping: A New Frontier or A Sisyphean Task? The evolution of AI from sassy recommendation tools to transaction-executing agents is shaking up the retail sector. Enter Stage Left: Yeahka Limited (9923.HK), a payment tech outfit that's wading into this murky digital swamp. With YeahPay and Fushi Tech, they're trying to hammer out a blueprint for AI-friendly commerce...

Continue Reading
Sola's 11-Step Push Makes Salon Ownership Less Blind

Updated Category News Views 124

A pristine studio does not pay rent by itself. That is the uncomfortable little truth sitting underneath Sola Salons’ new 11-step roadmap for beauty professionals considering salon-suite ownership. The company is telling stylists, estheticians, nail technicians, massage therapists, and other independent operators to treat the move from commission work to ownership like...

Continue Reading
Apani Adds Kelsun Assets to Its Natural Fiber Platform

Updated Category News Views 141

A materials deal with more chemistry than chest-thumping Seaweed and cotton have landed under one roof, which is a lot more interesting than another apparel brand slapping a green label on ordinary fabric. Apani said November 17 it acquired the assets of Keel Labs, bringing Keel's seaweed-based Kelsun fiber alongside Apani's enhanced cotton-cellulose filament technology....

Continue Reading
Medical School Rejections Carry a Steep Price Tag Too

Updated Category News Views 107

A rejection letter can turn into a remarkably expensive piece of paper. BeMo Academic Consulting's new Medical School Admissions Trends Report argues that the damage from missing medical-school admission goes far beyond bruised confidence: applicants can spend thousands chasing another cycle, lose time entering practice, and, if they never get in, forgo what the report...

Continue Reading
Suntory Flowers Tests NASCAR as a Garden Retail Engine

Updated Category News Views 73

Orange sheet metal and flowering vines are an odd couple, which is precisely why this South Florida promotion has some bite. A plant marketer took a hard left turn Suntory Flowers put its Sun Parasol mandevillas alongside DGM Racing at Homestead-Miami Speedway, celebrating the millions of plants grown in South Florida. That is not a conventional horticulture play, and...

Continue Reading

Top 5 Most Recently Viewed Articles

Coop Pank Reveals Q3 2025 Financial Results During Webinar

Updated Category News Views 161

Insights from Coop Pank's Recent Investor Webinar Coop Pank recently held an engaging investor webinar to discuss their unaudited financial results for the third quarter of 2025. During this informative session, Arko Kurtmann, the Chairman of the Management Board, and Paavo Truu, the Chief Financial Officer, elaborated on the bank's performance, highlighting significant...

Continue Reading
inTEST EMS Expands Market Reach Through New Distributor

Updated Category News Views 261

inTEST EMS Partners with General Bussan Co., Ltd. inTEST Electronic Test, part of inTEST Corporation (NYSE American: INTT), has announced a significant strategic partnership with General Bussan Co., Ltd. This collaboration is aimed at enhancing the distribution of inTEST EMS Products' high-quality manipulators, interface solutions, and docking systems designed...

Continue Reading
Gordon Brothers List Union Electric Steel Plant for Sale

Updated Category News Views 230

Gordon Brothers List Union Electric Steel Plant for Sale In the recent announcement, Gordon Brothers, renowned experts in asset management, are presenting a noteworthy opportunity for interested buyers. The entire roll manufacturing facility of Union Electric Steel Limited is now available for private sale, conducted by joint administrators. This facility is located in...

Continue Reading
AHLA Foundation's Summit Empowers Survivors and Experts

Updated Category News Views 157

Uniting Voices Against Human Trafficking The AHLA Foundation recently brought together a dynamic group of survivors, industry experts, and leaders at the No Room for Trafficking (NRFT) Summit. This significant event emphasized the importance of collaboration in the fight against human trafficking, focusing on education and the distribution of vital resources aimed at...

Continue Reading
Trump Media's Stock Reactions Amid Market Fluctuations Analysis

Updated Category News Views 158

Trump Media's Stock Takes a Hit Amid Insider Selling Concerns The shares of Trump Media have been quite turbulent lately, especially following reports that insiders within the company were given the green light to sell their holdings. This news is closely linked to former President Donald Trump, who has a significant stake in the company. Snapshot of Current Stock...

Continue Reading